Grufity logo
Grufity logo
THMO

THMO - ThermoGenesis Holdings Inc Stock Price, Fair Value and News

00
Market Closed as of 15 Jun 2026, 04:00 pm ET

Price Targets

00

THMO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

THMO Price Action

THMO RSI Chart

THMO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

THMO Valuation

Market Cap

0

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0

EV/EBITDA

0.07

Price/Free Cashflow

0

THMO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

00

THMO Fundamentals

THMO Revenue

THMO Earnings

THMO Profitability

Free Cashflow Yield

0%

THMO Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20249.6M---
202310.4M9.6M9.7M9.4M
202210.4M11.3M10.2M10.5M
20218.1M8.0M8.8M9.3M
202013.3M11.2M9.5M9.7M
201910.8M13.1M14.0M13.0M
201811.4M9.9M9.9M9.7M
201714.0M14.5M13.8M12.8M
201612.7M11.9M12.9M13.6M
201516.2M16.0M15.2M13.9M
201416.3M16.0M16.0M16.2M
201318.3M18.0M17.5M17.2M
201219.9M19.0M18.3M18.3M
201123.3M23.4M21.3M20.2M
2010-23.1M23.2M23.2M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About ThermoGenesis Holdings Inc

THMO
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
 CEO
 WEBSITEthermogenesis.com
 SECTORHealthcare
 INDUSTRYMedical Devices
 EMPLOYEES40

ThermoGenesis Holdings Inc Frequently Asked Questions

THMO is the stock ticker symbol of ThermoGenesis Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of ThermoGenesis Holdings Inc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, THMO's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. THMO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ThermoGenesis Holdings Inc has provided -1 (multiply by 100 for percentage) rate of return.